Laboratorios Farmaceuticos Rovi, S.A. (0ILL) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone. This is Martha Campos, Head of Finance for Rovi. Welcome to our company's review of business results for the first quarter of twenty twenty six. Before we begin, let me remind you that today's presentation and associated documentation are available on the Investor Relations section of Rovi's website. Please note that the information presented in this call contains forward looking statements based on our current beliefs and expectations. Actual results could materially differ due to known and unknown risks, uncertainties and other factors, and we undertake no obligation to update or revise any of the statements. Moving to today's agenda, Juan Lopez Belmonte, Rovi's Chairman and Chief Executive Officer, will discuss our business performance for the quarter. Javier Lopez Melmonte, Rovi's Deputy Chairman and Chief Financial Officer, will then review financial results. The presentation will be followed by a Q and A session. Therefore, if you want to ask any questions during the presentation, please do not hesitate to send them through the question button on the platform. With that, I thank you for your presence here today and will now turn the call over to Juan. Thank you, Matta, and thanks to everyone for joining us today. Let me start by addressing our outlook for 2026. In light of recent developments and greater visibility in key business drivers, we have revised our expectations for the full year. I will provide the strategic context, and Javier will then take you to the detailed financials. Let me continue what we have seen in the business during the first quarter of twenty twenty six. Operating revenues reached €152,500,000 representing a 1.5 percentage decrease compared to the first quarter of twenty twenty five, mainly due to the performance of the...